MA29915B1 - SUBSTITUTED BENZIMIDAZOLES AS KINASE INHIBITORS - Google Patents

SUBSTITUTED BENZIMIDAZOLES AS KINASE INHIBITORS

Info

Publication number
MA29915B1
MA29915B1 MA30737A MA30737A MA29915B1 MA 29915 B1 MA29915 B1 MA 29915B1 MA 30737 A MA30737 A MA 30737A MA 30737 A MA30737 A MA 30737A MA 29915 B1 MA29915 B1 MA 29915B1
Authority
MA
Morocco
Prior art keywords
compositions
new
kinase inhibitors
inhibiting
compounds
Prior art date
Application number
MA30737A
Other languages
French (fr)
Inventor
Mina E Aikawa
Payman Amiri
Jeffrey H Dove
Barry Haskell Levine
Christopher Mcbride
Teresa E Pick
Daniel J Poon
Savithri Ramurthy
Paul A Renhowe
Cynthia Shafer
Darrin Stuart
Sharadha Subramanian
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA29915B1 publication Critical patent/MA29915B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

CETTE INVENTION CONCERNE DES NOUVEAUX COMPOSÉS BENZIMIDAZOLES SUBSTITUÉS REPRÉSENTÉS PAR LA FORMULE (I). L'INVENTION CONCERNE ÉGALEMENT DES COMPOSITIONS, ET DES PROCÉDÉS PERMETTANT D'INHIBER L'ACTIVITÉ DES KINASES ASSOCIÉE À LA TUMORIGÉNÈSE CHEZ UN SUJET HUMAIN OU ANIMAL. DANS CERTAINS MODES DE RÉALISATION, LES COMPOSÉS ET LES COMPOSITIONS SONT EFFICACES POUR INHIBER L'ACTIVITÉ D'AU MOINS UNE SÉRINE/THRÉONINE KINASE OU UN RÉCEPTEUR TYROSINE KINASE. LES NOUVEAUX COMPOSÉS ET LES NOUVELLES COMPOSITIONS DE CETTE INVENTION PEUVENT ÊTRE UTILISÉS SEULS OU COMBINÉS AVEC AU MOINS UN AGENT SUPPLÉMENTAIRE POUR LE TRAITEMENT D'UN TROUBLE INDUIT PAR UNE SÉRINE/THRÉONINE KINASE OU PAR UN RÉCEPTEUR TYROSINE KINASE, TEL QUE LE CANCER.THIS INVENTION CONCERNS NEW SUBSTITUTED BENZIMIDAZOLE COMPOUNDS REPRESENTED BY FORMULA (I). The invention also relates to compositions and methods for inhibiting the activity of tumor-associated kinesias in a human or animal subject. In certain embodiments, the compounds and compositions are effective in inhibiting the activity of at least one serine / threonine kinase or a tyrosine kinase receptor. THE NEW COMPOUNDS AND THE NEW COMPOSITIONS OF THIS INVENTION MAY BE USED ONLY OR IN COMBINATION WITH AT LEAST ONE ADDITIONAL AGENT FOR THE TREATMENT OF A SERIN / THREONIN KINASE INDUCED DISORDER OR A TYROSINE KINASE RECEPTOR, SUCH AS CANCER.

MA30737A 2005-08-30 2008-03-11 SUBSTITUTED BENZIMIDAZOLES AS KINASE INHIBITORS MA29915B1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US71310805P 2005-08-30 2005-08-30
US71253905P 2005-08-30 2005-08-30
US73159105P 2005-10-27 2005-10-27
US77468406P 2006-02-17 2006-02-17

Publications (1)

Publication Number Publication Date
MA29915B1 true MA29915B1 (en) 2008-11-03

Family

ID=37434025

Family Applications (2)

Application Number Title Priority Date Filing Date
MA30737A MA29915B1 (en) 2005-08-30 2008-03-11 SUBSTITUTED BENZIMIDAZOLES AS KINASE INHIBITORS
MA30738A MA29772B1 (en) 2005-08-30 2008-03-11 SUBSTITUTED BENZIMIDAZOLES AND METHODS OF PREPARATION

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA30738A MA29772B1 (en) 2005-08-30 2008-03-11 SUBSTITUTED BENZIMIDAZOLES AND METHODS OF PREPARATION

Country Status (37)

Country Link
US (6) US7482367B2 (en)
EP (2) EP1924577B1 (en)
JP (4) JP5210867B2 (en)
KR (2) KR20080039965A (en)
AR (2) AR057109A1 (en)
AT (2) ATE503751T1 (en)
AU (2) AU2006284666B2 (en)
BR (2) BRPI0615309B1 (en)
CA (2) CA2620472C (en)
CR (1) CR9716A (en)
CU (1) CU23784B7 (en)
CY (2) CY1111871T1 (en)
DE (1) DE602006021036D1 (en)
DK (2) DK1926722T3 (en)
EA (1) EA014230B1 (en)
EC (2) ECSP088210A (en)
ES (1) ES2374451T3 (en)
GE (1) GEP20105004B (en)
GT (1) GT200600394A (en)
HK (2) HK1117519A1 (en)
HN (1) HN2008000317A (en)
HR (2) HRP20110312T1 (en)
IL (2) IL189080A (en)
MA (2) MA29915B1 (en)
MY (2) MY148694A (en)
NI (1) NI200800060A (en)
NO (1) NO20081476L (en)
NZ (2) NZ565451A (en)
PE (2) PE20070427A1 (en)
PL (2) PL1924577T3 (en)
PT (2) PT1926722E (en)
RS (1) RS52099B (en)
SI (2) SI1926722T1 (en)
SM (1) SMAP200800022A (en)
TN (2) TNSN08089A1 (en)
TW (2) TW200804345A (en)
WO (2) WO2007030377A1 (en)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200804345A (en) * 2005-08-30 2008-01-16 Novartis Ag Substituted benzimidazoles and methods of preparation
GB0609378D0 (en) * 2006-05-11 2006-06-21 Novartis Ag Organic compounds
DE602007005139D1 (en) * 2006-07-21 2010-04-15 Novartis Ag FORMULATIONS FOR BENZIMIDAZOLYLPYRIDYL ETHER
PE20080766A1 (en) * 2006-08-30 2008-06-15 Novartis Ag BENZIMIDAZOLYL PYRIDYL ETHER SALTS AND FORMULATIONS CONTAINING THEM
BRPI0716944A2 (en) * 2006-09-19 2013-09-17 Novartis Ag target modulation, efficacy, diagnostic, and / or prognostic biomarkers for raf inhibitors
MY148438A (en) * 2007-03-02 2013-04-30 Novartis Ag Solid forms of a raf kinase inhibitor
CA2686787A1 (en) * 2007-05-23 2008-12-04 Novartis Ag Raf inhibitors for the treatment of thyroid cancer
EP2162445B1 (en) 2007-06-05 2013-11-27 Takeda Pharmaceutical Company Limited Heterobicyclic compounds as kinase inhibitors
JP5270553B2 (en) 2007-08-23 2013-08-21 武田薬品工業株式会社 Heterocyclic compounds and uses thereof
WO2009028629A1 (en) * 2007-08-29 2009-03-05 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
CA2726376A1 (en) * 2008-06-13 2009-12-17 Novartis Ag Substituted benzimidazoles for neurofibromatosis
AU2009268469B2 (en) 2008-07-11 2013-02-28 Novartis Ag Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of Ras/Raf/Mek pathway
MX2011004505A (en) * 2008-10-29 2011-05-31 Merck Sharp & Dohme Novel cyclic benzimidazole derivatives useful anti-diabetic agents.
EP2399921B1 (en) 2008-12-01 2015-08-12 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
JO3101B1 (en) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co Benzothiazole derivatives as anticancer agents
JP2011020936A (en) * 2009-07-14 2011-02-03 Lotte Co Ltd Foul breath remover
JO3002B1 (en) 2009-08-28 2016-09-05 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2011044072A1 (en) 2009-10-05 2011-04-14 Novartis Ag Combination of raf-265 and an activator of ampk for use in the treatment of a proliferative disease
BR112013012485A2 (en) * 2010-11-19 2016-09-06 Glaxosmithkline Ip No 2 Ltd braf inhibitor treatment method
BR112013021941B1 (en) 2011-04-18 2022-11-16 Eisai R & D Management Co., Ltd THERAPEUTIC AGENT FOR TUMOR
WO2012145503A1 (en) 2011-04-21 2012-10-26 Novartis Ag Pharmaceutical combinations
EP2750675A1 (en) 2011-08-31 2014-07-09 Novartis AG Synergistic combinations of pi3k- and mek-inhibitors
CA2849566C (en) * 2011-11-09 2021-02-09 Cancer Research Technology Limited 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use
BR112014011223A8 (en) 2011-11-11 2023-01-31 Novartis Ag METHOD OF TREATMENT OF A PROLIFERATIVE DISEASE
CA2856406C (en) 2011-11-23 2020-06-23 Novartis Ag Pharmaceutical formulations
IN2014DN09221A (en) 2012-05-15 2015-07-10 Cancer Rec Tech Ltd
CA2890663A1 (en) 2012-11-08 2014-05-15 Novartis Ag Pharmaceutical combination comprising a b-raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases
CN105209073A (en) 2013-03-21 2015-12-30 诺华股份有限公司 Combination therapy comprising a B-Raf inhibitor and a second inhibitor
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
WO2015041533A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut Rock in combination with mapk-pathway
JOP20200094A1 (en) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc Antibody molecules to pd-1 and uses thereof
JOP20200096A1 (en) 2014-01-31 2017-06-16 Children’S Medical Center Corp Antibody molecules to tim-3 and uses thereof
UY36032A (en) 2014-03-14 2015-10-30 Novartis Ag ANTIBODY MOLECULES THAT JOIN LAG-3 AND USES OF THE SAME
US20170027940A1 (en) 2014-04-10 2017-02-02 Stichting Het Nederlands Kanker Instituut Method for treating cancer
WO2015178770A1 (en) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions for cancer treatment
MA41044A (en) 2014-10-08 2017-08-15 Novartis Ag COMPOSITIONS AND METHODS OF USE FOR INCREASED IMMUNE RESPONSE AND CANCER TREATMENT
WO2016061142A1 (en) 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof
US20170340733A1 (en) 2014-12-19 2017-11-30 Novartis Ag Combination therapies
AR103894A1 (en) 2015-03-10 2017-06-14 Aduro Biotech Inc COMPOSITIONS AND METHODS TO ACTIVATE THE DEPENDENT SIGNALING OF THE INTERFERON GEN STIMULATOR
US9890187B2 (en) 2015-06-26 2018-02-13 Epos-Iasis Research And Development, Ltd. Prototype systems of theranostic biomarkers for in vivo molecular management of cancer
CA3026466A1 (en) 2015-06-30 2017-01-05 Sequessome Technology Holdings Limited Blended formulations
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
CN114272371A (en) 2015-07-29 2022-04-05 诺华股份有限公司 Combination therapy comprising anti-PD-1 antibody molecules
DK3317301T3 (en) 2015-07-29 2021-06-28 Immutep Sas COMBINATION THERAPIES INCLUDING ANTIBODY MOLECULES AGAINST LAYER-3
SI3370768T1 (en) 2015-11-03 2022-04-29 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and their uses
CN105481944B (en) * 2015-12-10 2019-01-08 华南农业大学 A kind of two peptide copper complex of benzimidizole derivatives and its preparation method and application
CN108495651A (en) 2015-12-17 2018-09-04 诺华股份有限公司 The antibody molecule and application thereof of anti-PD-1
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
US11471538B2 (en) 2017-02-10 2022-10-18 INSERM (Institut National de la Santéet de la Recherche Medicale) Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the MAPK pathway
US11242332B2 (en) 2017-03-15 2022-02-08 Sumitomo Dainippon Pharma Co., Ltd. Method for producing benzimidazole derivative
CN117510405A (en) * 2017-04-18 2024-02-06 礼来公司 Phenyl-2-hydroxy-acetamido-2-methyl-phenyl compounds
UY37695A (en) 2017-04-28 2018-11-30 Novartis Ag BIS 2’-5’-RR- (3’F-A) (3’F-A) CYCLE DINUCLEOTIDE COMPOUND AND USES OF THE SAME
EP3642240A1 (en) 2017-06-22 2020-04-29 Novartis AG Antibody molecules to cd73 and uses thereof
SG11201912473PA (en) 2017-06-22 2020-01-30 Novartis Ag Antibody molecules to cd73 and uses thereof
CA3086765A1 (en) 2017-12-28 2019-07-04 Tract Pharmaceuticals, Inc. Stem cell culture systems for columnar epithelial stem cells, and uses related thereto
TW202015726A (en) 2018-05-30 2020-05-01 瑞士商諾華公司 Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
EP3876930A4 (en) * 2018-11-07 2022-07-20 Dana-Farber Cancer Institute, Inc. Benzimidazole derivatives and aza-benzimidazole derivatives as janus kinase 2 inhibitors and uses thereof
EP3908278A4 (en) 2019-01-11 2022-09-28 Naegis Pharmaceuticals Inc. Leukotriene synthesis inhibitors
JP2022548881A (en) 2019-09-18 2022-11-22 ノバルティス アーゲー ENTPD2 Antibodies, Combination Therapy and Methods of Using Antibodies and Combination Therapy
AU2021267373A1 (en) 2020-05-06 2022-12-08 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
AU2022388555A1 (en) 2021-11-09 2024-05-02 Ajax Therapeutics, Inc. 6-he tero aryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors

Family Cites Families (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3894037A (en) * 1971-05-24 1975-07-08 Ciba Geigy Corp Certain isothiocyanobenzimidazoles
IL54474A (en) * 1977-04-12 1982-04-30 Ciba Geigy Ag Benzimidazole derivatives,their preparation and anthelmintic compositions containing them
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4319039A (en) * 1979-06-15 1982-03-09 Merck & Co., Inc. Preparation of ammonium salt of hypocholesteremic fermentation product
US4294926A (en) * 1979-06-15 1981-10-13 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
MX7065E (en) * 1980-06-06 1987-04-10 Sankyo Co A MICROBIOLOGICAL PROCEDURE FOR PREPARING DERIVATIVES OF ML-236B
JPS5889191A (en) 1981-11-20 1983-05-27 Sankyo Co Ltd Preparation of 3-hydroxy-ml-236b derivative
US4430502A (en) * 1982-08-13 1984-02-07 The Upjohn Company Pyridinyl substituted benzimidazoles and quinoxalines
US5354772A (en) * 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4911165A (en) * 1983-01-12 1990-03-27 Ethicon, Inc. Pliabilized polypropylene surgical filaments
GB8307865D0 (en) * 1983-03-22 1983-04-27 Fujisawa Pharmaceutical Co Benzimidazole derivatives
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US4782084A (en) * 1987-06-29 1988-11-01 Merck & Co., Inc. HMG-COA reductase inhibitors
US4885314A (en) 1987-06-29 1989-12-05 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
US4820850A (en) * 1987-07-10 1989-04-11 Merck & Co., Inc. Process for α-C-alkylation of the 8-acyl group on mevinolin and analogs thereof
US5030447A (en) * 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
US5180589A (en) * 1988-03-31 1993-01-19 E. R. Squibb & Sons, Inc. Pravastatin pharmaceuatical compositions having good stability
US4916239A (en) * 1988-07-19 1990-04-10 Merck & Co., Inc. Process for the lactonization of mevinic acids and analogs thereof
US5290946A (en) * 1988-10-13 1994-03-01 Sandoz Ltd. Processes for the synthesis of 3-(substituted indolyl-2-yl)propenaldehydes
US5118853A (en) * 1988-10-13 1992-06-02 Sandoz Ltd. Processes for the synthesis of 3-disubstituted aminoacroleins
US4929437A (en) * 1989-02-02 1990-05-29 Merck & Co., Inc. Coenzyme Q10 with HMG-CoA reductase inhibitors
US5189164A (en) * 1989-05-22 1993-02-23 Sandoz Ltd. Processes for the synthesis of syn-(E)-3,5-dihydroxy-7-substituted hept-6-enoic and heptanoic acids and derivatives and intermediates thereof
FI94339C (en) 1989-07-21 1995-08-25 Warner Lambert Co Process for the preparation of pharmaceutically acceptable [R- (R *, R *)] - 2- (4-fluorophenyl) -, - dihydroxy-5- (1-methylethyl) -3-phenyl-4 - [(phenylamino) carbonyl] -1H- for the preparation of pyrrole-1-heptanoic acid and its pharmaceutically acceptable salts
PH27357A (en) * 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
JPH06759B2 (en) * 1989-09-22 1994-01-05 ファイザー製薬株式会社 Novel benzimidazole compound
US5420245A (en) * 1990-04-18 1995-05-30 Board Of Regents, The University Of Texas Tetrapeptide-based inhibitors of farnesyl transferase
US5041453A (en) * 1990-05-30 1991-08-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Quinolinyl-benzoheterobicyclic derivatives as antagonists of leukotriene D4
FR2677020B1 (en) * 1991-05-31 1993-08-27 Cird Galderma COMPOUNDS DERIVED FROM BENZIMIDAZOLE, THEIR PREPARATION PROCESS AND THEIR USE IN THE THERAPEUTIC AND COSMETIC FIELDS.
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
US5612360A (en) 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
US5604260A (en) * 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
CA2111902A1 (en) 1992-12-21 1994-06-22 Jack Beuford Campbell Antitumor compositions and methods of treatment
US5298627A (en) * 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5409944A (en) * 1993-03-12 1995-04-25 Merck Frosst Canada, Inc. Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
CA2118985A1 (en) 1993-04-02 1994-10-03 Dinesh V. Patel Heterocyclic inhibitors of farnesyl protein transferase
AU6909194A (en) * 1993-05-14 1994-12-12 Board Of Regents, The University Of Texas System Preparation of n-cyanodithioimino-carbonates and 3-mercapto-5-amino-1h-1,2,4-triazole
US5602098A (en) * 1993-05-18 1997-02-11 University Of Pittsburgh Inhibition of farnesyltransferase
US5380738A (en) * 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
GB9602877D0 (en) 1996-02-13 1996-04-10 Merck Frosst Canada Inc 3,4-Diaryl-2-hydroxy-2,5- dihydrofurans as prodrugs to cox-2 inhibitors
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5436265A (en) * 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
US5852046A (en) 1993-08-03 1998-12-22 Hoechst Aktiengesellschaft Benzo-fused heterocyclic compounds having a 5-membered ring processes for their preparation their use as medicaments their use as diagnostic agents and medicaments containing them
EP0639573A1 (en) 1993-08-03 1995-02-22 Hoechst Aktiengesellschaft Benzocondensed five membered heterocycles, process of their preparation, their use as drug, as diagnostic means and pharmaceuticals containing it
US5661152A (en) * 1993-10-15 1997-08-26 Schering Corporation Tricyclic sulfonamide compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5344991A (en) 1993-10-29 1994-09-06 G.D. Searle & Co. 1,2 diarylcyclopentenyl compounds for the treatment of inflammation
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5484799A (en) 1993-12-09 1996-01-16 Abbott Laboratories Antifungal dorrigocin derivatives
US5393790A (en) * 1994-02-10 1995-02-28 G.D. Searle & Co. Substituted spiro compounds for the treatment of inflammation
IL113196A0 (en) 1994-03-31 1995-06-29 Bristol Myers Squibb Co Imidazole derivatives and pharmaceutical compositions containing the same
US5523430A (en) * 1994-04-14 1996-06-04 Bristol-Myers Squibb Company Protein farnesyl transferase inhibitors
US5510510A (en) * 1994-05-10 1996-04-23 Bristol-Meyers Squibb Company Inhibitors of farnesyl protein transferase
US6391636B1 (en) * 1994-05-31 2002-05-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US6358932B1 (en) * 1994-05-31 2002-03-19 Isis Pharmaceticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US5571792A (en) * 1994-06-30 1996-11-05 Warner-Lambert Company Histidine and homohistidine derivatives as inhibitors of protein farnesyltransferase
CA2155448A1 (en) 1994-08-11 1996-02-12 Katerina Leftheris Inhibitors of farnesyl protein transferase
EP0701907A1 (en) 1994-09-13 1996-03-20 Agfa-Gevaert N.V. A dye donor element for use in a thermal dye transfer process
US6037136A (en) * 1994-10-24 2000-03-14 Cold Spring Harbor Laboratory Interactions between RaF proto-oncogenes and CDC25 phosphatases, and uses related thereto
US5741789A (en) * 1995-01-17 1998-04-21 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
US6001866A (en) 1995-10-05 1999-12-14 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US5717100A (en) * 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
US6020343A (en) * 1995-10-13 2000-02-01 Merck Frosst Canada, Inc. (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
EP1440973A3 (en) * 1995-11-17 2004-10-20 Gesellschaft für biotechnologische Forschung mbH (GBF) Epothilone derivatives, preparation and use
CN1211238A (en) * 1995-12-28 1999-03-17 藤泽药品工业株式会社 Benzimidazole derivatives
GB9602029D0 (en) * 1996-02-01 1996-04-03 Fujisawa Pharmaceutical Co New heterocyclic compounds
KR100387658B1 (en) * 1996-04-12 2003-08-19 지.디. 썰 엘엘씨 Substituted benzenesulfonamide derivatives as prodrugs of cox-2 inhibitors
JP2000511419A (en) * 1996-05-23 2000-09-05 アプライド・リサーチ・システムズ・エイアールエス・ホールディング・ナムローゼ・フェンノートシャップ Compound that inhibits binding of Raf-1 or 14-3-3 protein to IL-2 receptor β chain, and pharmaceutical composition containing the same
US5861419A (en) 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
FR2751649B1 (en) * 1996-07-26 1998-08-28 Adir NOVEL DERIVATIVES OF BENZIMIDAZOLE, BENZOXAZOLE AND BENZOTHIAZOLE, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AU756699B2 (en) * 1996-12-03 2003-01-23 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6127380A (en) * 1997-02-18 2000-10-03 American Home Products Corporation 4-aminoalkoxy-1H-benzoimidazoles
US5932600A (en) * 1997-03-14 1999-08-03 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
CA2282398A1 (en) * 1997-03-14 1998-09-17 Steven M. Ronkin Inhibitors of impdh enzyme
AR012634A1 (en) * 1997-05-02 2000-11-08 Sugen Inc QUINAZOLINE BASED COMPOUND, FAMACEUTICAL COMPOSITION THAT UNDERSTANDS IT, METHOD TO SYNTHESIZE IT, ITS USE, METHODS OF MODULATION OF THE DESERINE / TREONIN PROTEIN-KINASE FUNCTION AND IN VITRO METHOD TO IDENTIFY COMPOUNDS THAT MODULATE
US6187799B1 (en) * 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
KR20010020610A (en) * 1997-07-03 2001-03-15 해피 페너 ; 해리 에이치. 페너 2세 Certain diarylimidazole derivatives; a new class of npy specific ligands
SI9700186B (en) * 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Novel pharmaceutical preparation with controlled release of active healing substances
FR2766822B1 (en) * 1997-07-30 2001-02-23 Adir NOVEL DERIVATIVES OF BENZIMIDAZOLE, BENZOXAZOLE AND BENZOTHIAZOLE, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
GB9716557D0 (en) * 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6022884A (en) * 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6204467B1 (en) * 1998-03-24 2001-03-20 Ford Global Technologies, Inc. Method and apparatus for resistive welding
CA2332402A1 (en) * 1998-05-22 1999-12-02 Susan B. Dillon Novel 2-alkyl substituted imidazole compounds
US6420555B1 (en) * 1998-06-16 2002-07-16 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Imidazolyl derivatives
FR2780973B1 (en) * 1998-07-09 2001-10-05 Hoechst Marion Roussel Inc PROCESS FOR THE PREPARATION OF 4- (3-PYRIDINYL) -1H-IMIDAZOLE, AND THE INTERMEDIATES USED
DE19834751A1 (en) * 1998-08-01 2000-02-03 Boehringer Ingelheim Pharma Disubstituted bicyclic heterocycles, their preparation and their use as medicines
US6211177B1 (en) * 1998-11-24 2001-04-03 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives
RU2319693C9 (en) * 1999-01-13 2008-08-20 Байер Копэрейшн Derivatives of urea (variants), pharmaceutical composition (variants) and method for treatment of diseases associated with cancer cells growth (variants)
AU769554B2 (en) * 1999-04-12 2004-01-29 Aventis Pharma Limited Substituted bicyclic heteroaryl compounds as integrin antagonists
WO2001001986A1 (en) 1999-07-02 2001-01-11 Lipton Stuart A Method of reducing neuronal injury or apoptosis
EP1263753B1 (en) 2000-03-06 2004-05-06 SmithKline Beecham plc Imidazol derivatives as raf kinase inhibitors
WO2001072712A1 (en) 2000-03-24 2001-10-04 Cor Therapeutics, Inc. ISOQUINOLONE INHIBITORS OF FACTOR Xa
EP1272483A2 (en) 2000-03-24 2003-01-08 Millenium Pharmaceuticals, Inc. OXINDOLE INHIBITORS OF FACTOR Xa
JP2001322903A (en) 2000-05-15 2001-11-20 Kumiai Chem Ind Co Ltd Germicidal composition for agriculture and horticulture
EP1303305B1 (en) * 2000-07-27 2007-03-21 Pharmacia Corporation Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
WO2002018654A1 (en) * 2000-08-30 2002-03-07 The Board Of Trustees Of The University Of Arkansas Induction of ldl receptor expression by extracellular-signal regulated kinase, erk-1/2
JP4734705B2 (en) 2000-10-31 2011-07-27 三菱化学株式会社 Positive electrode material for lithium secondary battery, positive electrode for lithium secondary battery, and lithium secondary battery
DE10060292A1 (en) * 2000-12-05 2002-06-20 Aventis Pharma Gmbh Use of substituted benzimidazoles for the manufacture of a medicament for the treatment of diseases which can be influenced by inhibition of the Na + / H + exchanger and medicament containing them
MY138797A (en) * 2000-12-15 2009-07-31 Vertex Pharma Bacterial gyrase inhibitors and uses thereof
TW593278B (en) * 2001-01-23 2004-06-21 Wyeth Corp 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
JP2004531479A (en) * 2001-02-08 2004-10-14 カロ バイオ アクチェブラーグ Phenoxy-substituted benzofused heteroaryl derivatives as thyroid receptor ligands
EP1379242B1 (en) * 2001-03-26 2012-08-15 Newsouth Innovations Pty Limited Method for treatment of cancer and compositions for use therein
JP4073786B2 (en) * 2001-04-16 2008-04-09 田辺三菱製薬株式会社 High conductance calcium-sensitive K channel opener
US6855714B2 (en) * 2001-07-06 2005-02-15 Schering Aktiengesellschaft 1-alkyl-2-aryl-benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives
EP1427408A4 (en) 2001-09-17 2005-10-26 Bristol Myers Squibb Co CYCLIC HYDROXAMIC ACIDS AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-$g(a) CONVERTING ENZYME (TACE)
CA2458533C (en) * 2001-10-09 2011-01-04 Tularik Inc. Imidazole derivates as anti-inflammatory agents
US7039413B2 (en) * 2001-10-24 2006-05-02 Ntt Docomo, Inc. Mobile station transfer control system, cell transfer control method, mobile station, cell transfer control method at mobile station, cell transfer control program, control apparatus, and allocating method of communication resources
TW200300140A (en) 2001-11-14 2003-05-16 Novartis Ag Organic compounds
TW200303742A (en) 2001-11-21 2003-09-16 Novartis Ag Organic compounds
UA83620C2 (en) * 2001-12-05 2008-08-11 Уайт Substituted benzoxazoles and analogues as estrogenic agents
JP4136395B2 (en) 2002-02-22 2008-08-20 クミアイ化学工業株式会社 Agricultural / horticultural fungicide composition
US8299108B2 (en) * 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
EA007987B1 (en) * 2002-03-29 2007-02-27 Чирон Корпорейшн Substituted benzazoles and use thereof as raf kinase inhibitors
KR20040104596A (en) 2002-04-25 2004-12-10 데이진 가부시키가이샤 4,4-disubstituted piperidine derivatives having ccr3 antagonism
TW200400816A (en) * 2002-06-26 2004-01-16 Lilly Co Eli Tricyclic steroid hormone nuclear receptor modulators
AR040847A1 (en) 2002-08-09 2005-04-20 Astrazeneca Ab 1,2,4-OXADIAZOLES AS METABOTROPIC GLUTAMATE RECEPTORS MODULATORS, FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS
EA200500378A1 (en) * 2002-09-18 2005-08-25 Пфайзер Продактс Инк. NEW IMIDAZOL COMPOUNDS AS A TRANSFORMING GROWTH FACTOR INHIBITORS (TGF) INHIBITORS
AU2003271548A1 (en) 2002-10-13 2004-05-04 Neurosearch A/S Use of skca channel blocking drugs for combating parkinson's disease
JP4768265B2 (en) 2002-10-15 2011-09-07 シンタ ファーマシューティカルズ コーポレーション New compounds
US20050054705A1 (en) * 2003-02-04 2005-03-10 Aventis Pharma Deutschland Gmbh N-substituted (benzoimidazol-2-yl) phenylamines, process for their preparation, their use as medicament or diagnostic aid, and medicament comprising them
US7531553B2 (en) 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use
WO2004087153A2 (en) 2003-03-28 2004-10-14 Chiron Corporation Use of organic compounds for immunopotentiation
US7652061B2 (en) 2003-05-20 2010-01-26 Novartis A.G. N-acyl nitrogen heterocycles as ligands of peroxisome proliferator-activated receptors
AU2004251641A1 (en) 2003-05-29 2005-01-06 Synta Pharmaceuticals, Corp Heterocyclic compounds for preventing and treating disorders associated with excessive bone loss
US7538135B2 (en) 2003-07-08 2009-05-26 Novartis Ag Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds
EP1654251A4 (en) 2003-08-14 2009-03-11 Smithkline Beecham Corp Chemical compounds
DK2210607T3 (en) 2003-09-26 2011-12-12 Exelixis Inc N- [3-fluoro-4 - ({6- (methyloxy) -7 - [(3-morpholin-4-ylpropyl) oxy] quinolin-4-yl} oxy) phenyl] -N '- (4-fluorophenyl) cyclopropane-1,1-dicarboxamide for the treatment of cancer
WO2005037273A1 (en) * 2003-10-16 2005-04-28 Chiron Corporation Substituted benzazoles and use thereof as inhibitors of raf kinase
WO2005073224A2 (en) 2004-01-23 2005-08-11 Amgen Inc Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer
TW200804345A (en) * 2005-08-30 2008-01-16 Novartis Ag Substituted benzimidazoles and methods of preparation
DE602007005139D1 (en) * 2006-07-21 2010-04-15 Novartis Ag FORMULATIONS FOR BENZIMIDAZOLYLPYRIDYL ETHER

Also Published As

Publication number Publication date
BRPI0615309B1 (en) 2021-07-27
CA2620472C (en) 2013-12-24
AR055622A1 (en) 2007-08-29
ATE526325T1 (en) 2011-10-15
PE20070335A1 (en) 2007-04-21
KR20080039964A (en) 2008-05-07
PL1924577T3 (en) 2011-09-30
US7732465B2 (en) 2010-06-08
US20100256375A1 (en) 2010-10-07
KR20080039965A (en) 2008-05-07
IL189080A (en) 2013-05-30
US7482367B2 (en) 2009-01-27
AU2006284666A1 (en) 2007-03-08
PT1926722E (en) 2012-01-11
BRPI0615314A2 (en) 2011-05-17
US20100234394A1 (en) 2010-09-16
ECSP088218A (en) 2008-03-26
IL189194A0 (en) 2008-06-05
BRPI0615309A2 (en) 2011-05-17
SMP200800022B (en) 2008-04-02
PL1926722T3 (en) 2012-02-29
TNSN08089A1 (en) 2009-07-14
CU20080027A7 (en) 2010-12-08
EA014230B1 (en) 2010-10-29
WO2007030377A1 (en) 2007-03-15
NO20081476L (en) 2008-03-26
HRP20110939T1 (en) 2012-01-31
NZ565450A (en) 2011-04-29
AU2006284666B2 (en) 2011-04-28
HK1117523A1 (en) 2009-01-16
ECSP088210A (en) 2008-03-26
PT1924577E (en) 2011-07-04
DK1926722T3 (en) 2011-12-19
PE20070427A1 (en) 2007-04-21
TWI387592B (en) 2013-03-01
US8592459B2 (en) 2013-11-26
DK1924577T3 (en) 2011-05-16
US20090170904A1 (en) 2009-07-02
GEP20105004B (en) 2010-06-10
US20070161680A1 (en) 2007-07-12
TW200804346A (en) 2008-01-16
IL189194A (en) 2013-09-30
ES2374451T3 (en) 2012-02-16
CU23784B7 (en) 2012-02-15
NZ565451A (en) 2011-05-27
EP1924577B1 (en) 2011-03-30
JP2009507794A (en) 2009-02-26
US20080287682A1 (en) 2008-11-20
ATE503751T1 (en) 2011-04-15
JP5210866B2 (en) 2013-06-12
WO2007027950A1 (en) 2007-03-08
MY148694A (en) 2013-05-31
EP1924577A1 (en) 2008-05-28
DE602006021036D1 (en) 2011-05-12
SI1926722T1 (en) 2012-01-31
HK1117519A1 (en) 2009-01-16
JP2013060458A (en) 2013-04-04
MY163886A (en) 2017-11-15
US7767820B2 (en) 2010-08-03
EP1926722B1 (en) 2011-09-28
CA2619966A1 (en) 2007-03-08
RS52099B (en) 2012-06-30
AU2006287688B2 (en) 2010-08-19
CY1111871T1 (en) 2015-11-04
CR9716A (en) 2008-04-16
EA200800441A1 (en) 2008-08-29
HN2008000317A (en) 2011-02-16
NI200800060A (en) 2009-03-03
MA29772B1 (en) 2008-09-01
JP2013060457A (en) 2013-04-04
GT200600394A (en) 2008-03-17
TW200804345A (en) 2008-01-16
SI1924577T1 (en) 2011-07-29
CY1112157T1 (en) 2015-12-09
CA2620472A1 (en) 2007-03-15
HRP20110312T1 (en) 2011-08-31
SMAP200800022A (en) 2008-04-02
JP5210867B2 (en) 2013-06-12
IL189080A0 (en) 2008-08-07
TNSN08088A1 (en) 2009-07-14
US20070049622A1 (en) 2007-03-01
EP1926722A1 (en) 2008-06-04
AU2006287688A1 (en) 2007-03-15
JP2009507026A (en) 2009-02-19
AR057109A1 (en) 2007-11-14

Similar Documents

Publication Publication Date Title
MA29915B1 (en) SUBSTITUTED BENZIMIDAZOLES AS KINASE INHIBITORS
MA32684B1 (en) Picolinamide derivatives act as kinase inhibitors
MA32232B1 (en) Novel heterocyclic compounds and their uses
MA30607B1 (en) SUBSTITUTED N-PHENYLMETHYL -5-OXO-PROLINE-2-AMIDES INSTEAD OF P2X7 RECEPTOR ANTAGONISTS AND METHODS OF USE
ATE516803T1 (en) ARYL SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS
MA29160B1 (en) SUBSTITUTED TRIAZOLE DERIVATIVES AS OCYTOCIN ANTAGONISTS
ATE394400T1 (en) BICYCLIC ANILIDE SPIROHYDANTOINS AS CGRP RECEPTOR ANTAGONISTS
ATE556060T1 (en) MONOCYCLIC ANILIDE SPIROHYDANTOINS AS CGRP RECEPTOR ANTAGONISTS
MA29723B1 (en) COMPOUNDS
DE602005023963D1 (en) OTHER HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS ANTAGONISTS OF THE METABOTROPIC GLUTAMATE RECEPTOR
TNSN04111A1 (en) QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH
BRPI0515532A (en) compound, pharmaceutical composition, methods of inhibiting the binding of endogenous ligands to the crth-2 receptor in a cell, treating, ameliorating or preventing a disorder responsive to inhibiting the binding of endogenous ligands to the crt-2 receptor and preparing a compound. and kit
MA29797B1 (en) DERIVATIVES OF PYRROLOPYRIMIDINE INHIBITORS OF SYK
MA30655B1 (en) ORGANIC COMPOUNDS.
MA31457B1 (en) N- (2- (HETARYL) ARYL) ARYLSULFONAMIDES AND N- (2- (HETARYL) HETARYL) ARYLSULFONAMIDES
TW200505903A (en) CGRP receptor antagonists
MA31158B1 (en) Tricyclic compounds and their use as modifiers for glucocorticoid receptors.
EA200600048A1 (en) BENZAZEPIN DERIVATIVES USED TO TREAT DISEASES ASSOCIATED WITH 5-HT RECEPTOR
EA200501504A1 (en) Cannabinoid receptor ligands and their use
ATE535514T1 (en) CARBOXAMIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS
MA30906B1 (en) COMPOUNDS AND COMPOSITIONS AS QUINHIBITORS OF PROTEINS KINASES
MA31766B1 (en) ORGANIC COMPOUNDS
MA34300B1 (en) HETEROCYCLIC NITROGENIC COMPOUNDS AS PDE10 INHIBITORS
NO20092470L (en) Substituted diazepan compounds as orexin receptor antagonists
CY1110882T1 (en) ORXIN SUBSTITUTED DIAZEPAN RECEPTOR COMPETITORS